$ENVA

RICE LINDA JOHNSON sold $210K of ENVA

RICE LINDA JOHNSON sold 1,300 shares of Enova International, Inc. (ENVA) at $161.20 ($0.21M total) on 2026-05-29.

Original reporting
SEC EDGAR · RICE LINDA JOHNSON
Published Jun 2, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:09 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ENVA
Neutral
medium confidence
Mentioned
$ENVA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ENVANeutralLow
01

Why it matters

A director’s open-market sale is disclosed, but the text contains no new company performance, guidance, or regulatory development.

02

Market read

Traders may note the insider sale for sentiment, but there is no fundamental catalyst in the text.

03

What to watch

The article does not state whether other insiders sold/bought, whether there were option exercises, or whether the sale was part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-02 for a sale dated 2026-05-29.

Background

The article is an SEC Form 4 insider transaction disclosure for Enova International, Inc.

Company-level read

Ticker impact

$ENVANeutralMedium confidence
Context

Director Rice Linda Johnson filed a Form 4 open-market sale of 1,300 ENVA shares at $161.1968 on 2026-05-29.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but the article provides only a single sale transaction size and no accompanying guidance, operational update, or enforcement/regulatory event.

Market effects

No sector read-through is provided beyond a single insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so this may not reflect bearish fundamentals.

Key entities

  • Enova International, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • RICE LINDA JOHNSON

    Director who sold 1,300 shares in an open-market transaction.

Related articles

$OPFIMed

OppFi and Enova Bank Deals Put Lending Under Scrutiny

Attorneys general asked the Federal Reserve, OCC and FDIC to deny banking privileges tied to OppFi’s $130M acquisition of BNCCORP and BNC National Bank and Enova’s proposed acquisition of Grasshopper Bancorp and Grasshopper Bank. AGs allege bank partnerships bypass state loan-rate caps and cite high rates and charge-offs. OppFi and Enova project deposit and revenue synergies and EPS accretion.

$ENVAMed

ENVA Rallies As Enova Tops Q2 And Targets Grasshopper Bank Synergies

Enova International Inc. (NYSE: ENVA) shares rose about 9% after Q2 results and guidance-related optimism. The company reported adjusted EPS of $4.31 vs $3.96 consensus and revenue of $928.9M vs $764M prior year, with operating cash flow of $544M and $531.4M free cash flow. Analysts reportedly raised price targets to $257-$280, citing the Grasshopper Bank acquisition and improving credit metrics.

$ENVAMedAI 8/10

Enova International Stock Jumps After Powerful Q2 Beat

Enova International Inc. (NYSE: ENVA) shares rose about 9% during the week after the company reported Q2 2026 results and raised guidance. Adjusted EPS was $4.31 versus $3.96 expected, with revenue up to $928.9M from $764M. Management cited record $5.5B loans, improving margins, and ongoing share repurchases.

$ENVAMed

ENVA Jumps As Enova Earnings Beat Fuels Bullish Targets

Enova International Inc. (NYSE: ENVA) shares rose about 9% after its Q2 2026 results. The company reported adjusted EPS of $4.31 versus $3.23 a year earlier and revenue of $928.9M versus $764M, alongside a consumer credit outlook. Analysts cited bullish targets of $257 to $280 and support near $230.

$ENVAMedAI 8/10

Enova International Signals Strong Growth and Rising EPS

Enova International (ENVA) reported Q2 results and said consolidated originations rose 27% YoY to nearly $2.3B and total revenue rose 22% to $929M. Adjusted EPS increased 33% YoY to $4.31. Credit metrics improved, with net charge-offs at 7.3%. Management raised Q3 and 2026 guidance and noted the pending Grasshopper Bank deal awaits regulatory approval.

$ENVAMedAI 8/10

Enova Reports Second Quarter 2026 Results

Enova International (NYSE: ENVA) reported Q2 2026 results. Total revenue rose 22% to $929 million. Diluted EPS was $4.00, up 40%, and adjusted EPS was $4.31, up 33%. Credit metrics stayed strong, with net charge-offs at a 7.3% ratio and net revenue margin at 61%. Enova also repurchased $19 million of stock and reported $929 million liquidity at June 30.